Cargando…

Non-classical MHC Class I molecules regulating natural killer cell function

Natural killer (NK) cells possess effector and immunoregulatory functions that are controlled by a myriad of receptor-ligand pairs, including human killer inhibitory receptor (KIR) and mouse Ly49-MHC class I interactions. We have recently shown that the NK cell inhibitory molecule Ly49A binds the no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smyth, Mark J., Sullivan, Lucy C., Brooks, Andrew G., Andrews, Daniel M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661161/ https://www.ncbi.nlm.nih.gov/pubmed/23802076 http://dx.doi.org/10.4161/onci.23336

Ejemplares similares

MHC-I genotype drives early immune selection of oncogenic mutations
por: Marty, Rachel, et al.
Publicado: (2018)

Immunosurveillance of senescent cancer cells by natural killer cells
por: Iannello, Alexandre, et al.
Publicado: (2014)

ATM activation mediates anticancer immunosurveillance by natural killer and T cells
por: Tang, Melissa LF, et al.
Publicado: (2013)

Natural killer T cell strategies to combat Epstein–Barr virus infection
por: Priatel, John J, et al.
Publicado: (2014)

Role of non-classical MHC class I molecules in cancer immunosuppression
por: Kochan, Grazyna, et al.
Publicado: (2013)

Structure of a Classical MHC Class I Molecule That Binds “Non-Classical” Ligands
por: Hee, Chee Seng, et al.
Publicado: (2010)

KLRG1(+) natural killer cells protect against pulmonary metastatic disease by immunosurveillance
por: Renner, Philipp, et al.
Publicado: (2014)

A critical role for natural killer cells in dendritic cell-based anticancer immunotherapy
por: McLellan, Alexander D
Publicado: (2014)

Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype
por: Kellner, Christian, et al.
Publicado: (2013)

Type II natural killer T cells foster the antitumor activity of CpG-oligodeoxynucleotides
por: Zhao, Jie, et al.
Publicado: (2014)

Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable therapeutic target
por: Noman, Muhammad Zaeem, et al.
Publicado: (2018)

Adaptations of Natural Killer Cells to Self-MHC Class I
por: Bessoles, Stéphanie, et al.
Publicado: (2014)

Invariant natural killer T cells reconstitution and the control of leukemia relapse in pediatric haploidentical hematopoietic stem cell transplantation
por: Casorati, Giulia, et al.
Publicado: (2012)

Invariant NKT cells: Killers and conspirators against cancer
por: Bassiri, Hamid, et al.
Publicado: (2013)

Non-conventional sources of peptides presented by MHC class I
por: Starck, Shelley R., et al.
Publicado: (2011)

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
por: Shen, Li, et al.
Publicado: (2012)

Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity
por: Schendel, Dolores J., et al.
Publicado: (2013)

Activation of cytomegalovirus-specific CD8(+) T-cell response by antibody-mediated peptide-major histocompatibility class I complexes
por: Schmittnaegel, Martina, et al.
Publicado: (2015)

Activity of cytokine-induced killer cells against bone and soft tissue sarcoma
por: Sangiolo, Dario, et al.
Publicado: (2014)

MHC class I–deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I–sufficient environment
por: Elliott, Julie M., et al.
Publicado: (2010)

NKT cell adjuvants in therapeutic vaccines against hematological cancers
por: Mattarollo, Stephen R., et al.
Publicado: (2013)

Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression
por: Smyth, Mark J, et al.
Publicado: (2014)

Inducible down-regulation of MHC class I results in natural killer cell tolerance
por: Bern, Michael D., et al.
Publicado: (2019)

The anticancer effects of HDAC inhibitors require the immune system
por: West, Alison C, et al.
Publicado: (2014)

Hypoxia-driven immunosuppression contributes to the pre-metastatic niche
por: Sceneay, Jaclyn, et al.
Publicado: (2013)

The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects
por: West, Alison C., et al.
Publicado: (2012)

Natural Killer Cell Interactions with Classical and Non-Classical Human Leukocyte Antigen Class I in HIV-1 Infection
por: Hölzemer, Angelique, et al.
Publicado: (2017)

Restoration of tumor suppressor functions by small-molecule inhibitors
por: Pyndiah, Slovénie, et al.
Publicado: (2015)

A(2A) blockade enhances anti-metastatic immune responses
por: Beavis, Paul A, et al.
Publicado: (2013)

Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies
por: Verbrugge, Inge, et al.
Publicado: (2012)

Membrane-anchored chemokine fusion proteins: A novel class of adjuvants for immunotherapy
por: Nelson, Peter J, et al.
Publicado: (2013)

A novel small-molecule inhibitor of 3-phosphoglycerate dehydrogenase
por: Mullarky, Edouard, et al.
Publicado: (2016)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

Natural-killer cell ligands at the maternal–fetal interface: UL-16 binding proteins, MHC class-I chain related molecules, HLA-F and CD48
por: Apps, Richard, et al.
Publicado: (2008)

Targeting COX-2 abrogates mammary tumorigenesis: Breaking cancer-associated suppression of immunosurveillance
por: Markosyan, Nune, et al.
Publicado: (2014)

The role of the proteasome in the generation of MHC class I ligands and immune responses
por: Sijts, E. J. A. M., et al.
Publicado: (2011)

Targeting the coding sequence: opposing roles in regulating classical and non-classical MHC class I molecules by miR-16 and miR-744
por: Friedrich, Michael, et al.
Publicado: (2020)

The control of tumor vessels: what you would not expect from a neural adhesion molecule
por: Angiolini, Francesca, et al.
Publicado: (2015)

Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
por: Rudqvist, Nils-Petter, et al.
Publicado: (2023)

Naturally circulating dendritic cells to vaccinate cancer patients
por: Bol, Kalijn F., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_f9n81qr66kak448pvth3u4lprd